Rifampicin reduces advanced glycation end products and activates DAF-16 to increase lifespan in Caenorhabditis elegans

Rifampicin reduces advanced glycation end products and activates DAF-16 to increase lifespan in Caenorhabditis elegans

Advanced glycation end products (AGEs) are formed when glucose reacts nonenzymatically with proteins; these modifications are implicated in aging and pathogenesis of many age-related diseases including type II diabetes, atherosclerosis, and neurodegenerative disorders. Thus, pharmaceutical intervent...

Full description

Bibliographic Details
Main Authors: Golegaonkar, Sandeep, Tabrez, Syed S, Pandit, Awadhesh, Sethurathinam, Shalini, Jagadeeshaprasad, Mashanipalya G, Bansode, Sneha, Sampathkumar, Srinivasa-Gopalan, Kulkarni, Mahesh J, Mukhopadhyay, Arnab
Format: Online
Language:English
Published: BlackWell Publishing Ltd 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406675/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406675/

Similar Items